Universe Pharmaceuticals INC
UPC Healthcare Drug Manufacturers Specialty & Generic
Universe Pharmaceuticals INC’s revenue for fiscal 2025 (year ended September 2025) was $17.9 million, down 22.4% from fiscal 2024.
Follow UPC
Universe Pharmaceuticals INC (UPC) EV/Sales
As of 16 October 2026, Universe Pharmaceuticals INC (UPC) trades at a EV/Sales of −0.2×. Over the past ten years it has ranged from −0.5× (September 2025) to 0.0× (March 2024); the current reading is higher than 46% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.3× | — |
| FY2024 | −0.3× | — |
| FY2023 | 0.0× | — |
| FY2022 | −0.2× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2023 | 92.0× | 10.20% |
| Sep 2022 | 83.5× | — |
| Mar 2022 | 0.0× | — |
| Sep 2021 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IXHL Incannex Healthcare Inc. compare | −19.9× |
| UPC Universe Pharmaceuticals INC | −0.2× |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | n/m |
| BGXXQ Bright Green Corporation compare | n/m |
| RMTI Rockwell Medical, Inc. compare | 0.2× |
| BFRI Biofrontera Inc. compare | 0.2× |
| AYTU Aytu BioPharma, Inc. compare | 0.3× |
| CPHI China Pharma Holdings, Inc. compare | 8.1× |
| TXMD TherapeuticsMD, Inc. compare | 85.1× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)